Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
Users online: 7091  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page

    Article Cited by others


Itolizumab in psoriasis

Srivastava Ankita

Year : 2017| Volume: 62| Issue : 4 | Page no: 418-421

   This article has been cited by
1 Clinical course of critically ill non-COVID 19 ARDS patients using Itolizumab versus conventional treatment: A case series
Manimaran Rajendran
IP Indian Journal of Immunology and Respiratory Medicine. 2022; 7(2): 93
[Pubmed]  [Google Scholar] [DOI]
2 Asthmatic patientís preferences regarding frequency of physician consultation
Javeria Farooq, Sheikh Abdul Khaliq, Iqbal Azhar
Saudi Pharmaceutical Journal. 2021; 29(2): 201
[Pubmed]  [Google Scholar] [DOI]
3 A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Suresh Kumar, Rosemarie De Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank R. Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye
Expert Opinion on Biological Therapy. 2021; 21(5): 675
[Pubmed]  [Google Scholar] [DOI]
4 Treatment Modalities of Psoriasis: A Focus on Requisite for Topical Nanocarrier
Arya K. Ramanunny, Sheetu Wadhwa, Divya Thakur, Sachin K. Singh, Rajesh Kumar
Endocrine, Metabolic & Immune Disorders - Drug Targets. 2021; 21(3): 418
[Pubmed]  [Google Scholar] [DOI]
5 The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment
Stephen G. Gaffney, Elizabeth B. Perry, Ping-Min Chen, Andrew Greenstein, Susan M. Kaech, Jeffrey P. Townsend
Oncotarget. 2019; 10(44): 4532
[Pubmed]  [Google Scholar] [DOI]


Read this article